查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2129223

獸醫再生醫學市場預測至2034年—按產品類型、動物種類、應用、最終用戶和地區分類的全球分析

Veterinary Regenerative Medicine Market Forecasts to 2034 - Global Analysis By Product Type, Animal Type, Application, End User, and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球獸醫再生醫學市場規模將達到 4.372 億美元，在預測期內以 12.6% 的複合年成長率成長，到 2034 年將達到 11.299 億美元。

獸醫再生醫學是指利用動物自身修復機制來修復、替換或再生受損組織和器官的先進治療方法。此領域包括幹細胞療法、富血小板血漿（PRP）、骨髓抽吸物濃縮液（BMAC）、生長因子療法、組織工程產品和生物材料、利用細胞外囊泡和外泌體的療法以及其他再生醫學產品。該市場的目標群體包括伴侶動物、馬匹、牲畜和其他動物物種。

寵物數量的增加以及對先進獸醫治療需求的成長

全球寵物數量的不斷成長以及對先進獸醫學日益成長的需求是推動獸醫再生醫學市場發展的主要因素。寵物飼主越來越將寵物視為家庭成員，並尋求與人類醫療保健相媲美的尖端治療方案。隨著寵物越來越“擬人化”，人們也越來越願意投資於先進療法，例如幹細胞療法和富血小板血漿（PRP）療法，以治療骨關節炎、肌腱損傷和退化性關節疾病等。隨著寵物飼主和獸醫對再生醫學益處的認知不斷提高，伴侶動物和馬匹領域對這些先進療法的需求也在成長，從而推動了市場的強勁成長。

高昂的醫療成本與不完善的法律規範

再生醫學治療費用高昂，且獸醫再生醫學產品缺乏法規結構，這是限制市場發展的主要因素。幹細胞療法、富血小板血漿（PRP）療法和其他再生醫學療法需要專門的設備、設施和專業技術，導致治療費用居高不下。寵物保險對再生醫學的保障範圍仍然有限。在許多地區，獸醫再生醫學產品的監管管道尚未完善，為產品開發和商業化帶來了不不確定性。這些成本和監管障礙會限制再生醫學的普及，尤其是在價格敏感的寵物飼主以及監管基礎設施薄弱的地區。

幹細胞研究和外泌體療法的進展

幹細胞研究的持續創新和外泌體療法的興起為市場拓展帶來了巨大的機會。源自脂肪組織、骨髓和臍帶的間質幹細胞正被擴大用於治療骨關節炎、肌腱損傷和發炎性疾病。外泌體療法提供了一種無細胞再生醫學選擇，且監管更為簡單。對再生醫學新應用的研究，包括神經系統疾病、腎臟疾病和創傷治療等領域，正在擴大目標市場。隨著研究的深入和臨床證據的積累，新的治療用途和改進的治療方案正在不斷擴大市場佔有率。

與傳統療法和替代療法的競爭

來自抗發炎藥物、手術和物理治療等傳統療法的激烈競爭對再生醫學市場構成重大威脅。許多獸醫和寵物飼主仍然不熟悉再生醫學療法。傳統療法可能被認為更可預測且更具成本效益。針灸和脊骨神經醫學等替代療法也被視為價格較低的選擇。再生醫學專業人員數量有限也可能是阻礙其普及的因素。這些競爭可能會限制市場成長，尤其是在較保守的獸醫和對價格敏感的寵物飼主中。

新型冠狀病毒（COVID-19）的影響：

新冠疫情對獸醫再生醫學市場產生了多方面的影響。初期，疫情封鎖期間非必要的獸醫就診量減少，以及生物材料供應鏈中斷，都對市場造成了衝擊。然而，疫情期間寵物數量激增，擴大了目標市場。這場危機進一步提升了人們對寵物健康和福祉的關注，以及對先進療法的興趣。再生醫學遠距醫療也得到了發展。疫情後，寵物飼養量的成長和人們對先進寵物醫療保健的持續關注，維持了市場需求，再生醫學也越來越被獸醫和寵物飼主所接受。

在預測期內，「幹細胞療法」細分市場預計將佔據最大的市場佔有率。

在預測期內，幹細胞療法預計將佔據最大的市場佔有率，這主要得益於其成熟的臨床應用、不斷成長的科學證據以及在獸醫診所中日益廣泛的應用。間質幹細胞可用於治療犬、貓和馬的骨關節炎、肌腱和韌帶損傷以及發炎性疾病。此領域擁有​​成熟的細胞採集、處理和給藥方案，具有顯著優勢。獸醫和寵物飼主對幹細胞療法益處的認知不斷提高，推動了其應用。隨著臨床證據的累積和應用範圍的擴大，幹細胞療法將繼續保持其在產品細分市場中的領先地位。

預計在預測期內，伴侶動物細分市場將呈現最高的複合年成長率。

在預測期內，伴侶動物市場預計將呈現最高的成長率，這主要得益於犬貓數量龐大且持續成長、寵物「人性化」趨勢的日益明顯，以及對伴侶動物先進治療方案需求的不斷增加。犬貓是再生醫學的主要目標群體，包括用於治療骨關節炎和軟組織損傷的幹細胞療法和富血小板血漿（PRP）療法。寵物飼主願意投資先進治療方案，也為市場帶來了正面影響。此外，獸醫對伴侶動物再生醫學方案的認知不斷提高，也推動了其應用。在寵物「人性化」趨勢持續發展和健康意識不斷增強的背景下，伴侶動物市場在各類動物中呈現最快的成長速度。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這主要得益於其較高的寵物擁有率、大量的獸醫護理支出以及先進的獸醫基礎設施。美國透過對獸醫再生醫學的研究和臨床應用的大量投資，推動了區域市場的成長。寵物飼主和獸醫對先進療法的認知不斷提高，促進了這項技術的應用。再生醫學產品製造商和研究機構的存在為創新提供了支持。完善的獸醫轉診網路和專科診所則為就醫提供了便利。由於寵物支出高且獸醫基礎設施完善，北美在市場中保持主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於寵物擁有量的成長、可支配收入的增加、人們對先進獸醫學的認知不斷提高，以及中國、日本、澳大利亞和東南亞等國家獸醫基礎設施的不斷完善。該地區寵物擁有量的快速成長和中產階級的壯大，正在催生對先進治療的巨大需求。對獸醫教育和專業訓練投入的增加，正在提升再生醫學的能力。寵物保險覆蓋範圍的擴大也有助於減輕治療費用負擔。隨著獸醫保健的發展和人們對再生醫學的認知不斷提高，亞太地區正經歷著全球成長最快的獸醫再生醫學市場。

免費客製化服務：

所有購買此報告的客戶均可從以下免費自訂選項中選擇一項：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶要求，我們可以提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、地理覆蓋範圍和策略聯盟對領先公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰和機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章：全球獸醫再生醫學市場：依產品類型分類

  • 幹細胞療法
    • 間質幹細胞（MSCs）
    • 脂肪來源幹細胞
    • 骨髓來源幹細胞
    • 臍帶來源幹細胞
    • 其他類型的幹細胞
  • 富血小板血漿（PRP）
  • 骨髓抽吸物濃縮液（BMAC）
  • 生長因子療法
  • 組織工程產品和生物材料
    • 鷹架材料
    • 生物基質
  • 利用細胞外囊泡和外泌體的療法
  • 其他再生醫學產品

第6章：全球獸醫再生醫學市場：依動物類型分類

  • 伴侶動物
    • 狗
    • 貓
  • 馬
    • 賽馬
    • 比賽用馬和運動用馬
    • 休閒馬匹
  • 家畜
    • 牛
    • 豬
    • 家禽
  • 其他動物

第7章：全球獸醫再生醫學市場：依應用領域分類

  • 整形外科和肌肉骨骼疾病
    • 骨關節炎和關節疾病
    • 肌腱和韌帶損傷
    • 骨折和骨骼修復
    • 軟骨修復
  • 創傷和創傷護理
    • 急性傷口
    • 慢性傷口
    • 外科性創傷癒合
  • 皮膚病學和皮膚修復
  • 神經病學和神經再生
  • 心臟病學和心血管修復
  • 眼科學與眼部再生
  • 牙齒和口腔組織再生
  • 內臟器官修復
  • 其他用途

第8章：全球獸醫再生醫學市場：依最終用戶分類

  • 獸醫醫院及專科治療中心
  • 獨立動物醫院
  • 獸醫研究機構和學術機構
  • 獸醫復健中心
  • 生物技術和製藥公司
  • 其他最終用戶

第9章：全球獸醫再生醫學市場：依地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第10章 戰略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第11章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第12章：公司簡介

  • VetStem Biopharma, Inc.
  • Zoetis Inc.
  • Boehringer Ingelheim International GmbH
  • Dechra Pharmaceuticals Limited
  • Ardent Animal Health
  • Medrego Ltd.
  • Vetbiologics
  • Vetherapy
  • Celavet
  • Integra LifeSciences Holdings Corporation
  • Gallant Therapeutics
  • Enso Discoveries
  • Animal Cell Therapies
  • VetCell Therapeutics
  • Magellan BioMedical
  • KeraVet Bio
  • VetStem Europe
  • EquiCell
Product Code: SMRC39448

According to Stratistics MRC, the Global Veterinary Regenerative Medicine Market is accounted for $437.2 million in 2026 and is expected to reach $1129.9 million by 2034 growing at a CAGR of 12.6% during the forecast period. Veterinary regenerative medicine encompasses advanced therapeutic approaches that harness the body's natural healing mechanisms to repair, replace, or regenerate damaged tissues and organs in animals. This field includes stem cell therapy, platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), growth factor therapies, tissue engineering products and biomaterials, extracellular vesicles and exosome-based therapies, and other regenerative products. The market serves companion animals, equine, livestock animals, and other animal types.

Market Dynamics:

Driver:

Increasing pet ownership and demand for advanced veterinary treatments

The rising global pet population and growing demand for sophisticated, advanced veterinary treatments are primary drivers for the veterinary regenerative medicine market. Pet owners increasingly consider their animals as family members and seek cutting-edge therapeutic options comparable to human healthcare. The humanization of pets has led to greater willingness to invest in advanced treatments including stem cell therapy and PRP for conditions such as osteoarthritis, tendon injuries, and degenerative joint disease. As awareness of regenerative medicine benefits grows among pet owners and veterinarians, demand for these advanced therapies expands across companion animal and equine segments, sustaining strong market growth.

Restraint:

High treatment costs and limited regulatory frameworks

The significant costs associated with regenerative medicine procedures and limited regulatory frameworks for veterinary regenerative products represent a major restraint for the market. Stem cell therapy, PRP, and other regenerative treatments require specialized equipment, facilities, and expertise, resulting in high procedure costs. Pet insurance coverage for regenerative therapies remains limited. Regulatory pathways for veterinary regenerative products are not well-established in many regions, creating uncertainty for product development and commercialization. These cost and regulatory barriers may limit adoption, particularly among price-sensitive pet owners and in regions with limited regulatory infrastructure.

Opportunity:

Advancements in stem cell research and exosome-based therapies

Continuous innovation in stem cell research and the emergence of exosome-based therapies present significant opportunities for market expansion. Mesenchymal stem cells derived from adipose tissue, bone marrow, and umbilical cord are increasingly used for treating osteoarthritis, tendon injuries, and inflammatory conditions. Exosome-based therapies offer cell-free regenerative options with reduced regulatory complexity. Research into new applications for regenerative medicine including neurological disorders, renal disease, and wound healing is expanding the addressable market. As research advances and clinical evidence accumulates, new therapeutic applications and improved treatment protocols capture growing market share.

Threat:

Competition from conventional treatments and alternative therapies

Intense competition from conventional treatments including anti-inflammatory medications, surgery, and physical therapy poses significant threats to the regenerative medicine market. Many veterinarians and pet owners remain unfamiliar with regenerative options. Conventional treatments may be perceived as more predictable and cost-effective. Alternative therapies including acupuncture and chiropractic care offer lower-cost options. The limited availability of specialists trained in regenerative medicine may restrict adoption. This competition may constrain market growth, particularly among conservative practitioners and price-sensitive pet owners.

Covid-19 Impact:

The COVID-19 pandemic had a mixed impact on the veterinary regenerative medicine market. Initial disruptions included reduced non-emergency veterinary visits during lockdowns and supply chain interruptions for biological materials. However, pet adoption surged during the pandemic, expanding the addressable market. The crisis heightened focus on pet health and well-being, increasing interest in advanced treatment options. Telemedicine consultations for regenerative medicine expanded. Post-pandemic, elevated pet ownership and continued focus on advanced pet healthcare have sustained demand, with regenerative medicine gaining increasing acceptance among veterinarians and pet owners.

The Stem Cell Therapy segment is expected to be the largest during the forecast period

The Stem Cell Therapy segment is expected to account for the largest market share during the forecast period, driven by its established clinical applications, growing evidence base, and expanding availability across veterinary practices. Mesenchymal stem cells are used to treat osteoarthritis, tendon and ligament injuries, and inflammatory conditions in dogs, cats, and horses. The segment benefits from established protocols for cell harvesting, processing, and administration. Growing awareness among veterinarians and pet owners of stem cell therapy benefits drives adoption. As clinical evidence accumulates and applications expand, stem cell therapy maintains the largest product segment share.

The Companion Animals segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the Companion Animals segment is predicted to witness the highest growth rate, fueled by the large and growing dog and cat populations, increasing pet humanization, and rising demand for advanced treatments in companion animal practice. Dogs and cats are the primary recipients of regenerative therapies including stem cell therapy and PRP for osteoarthritis and soft tissue injuries. The segment benefits from strong pet owner willingness to invest in advanced treatments. Growing awareness of regenerative options among companion animal veterinarians supports adoption. As pet humanization and health awareness continue growing, companion animals deliver the fastest animal type segment growth.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, supported by high pet ownership rates, strong spending on veterinary care, and advanced veterinary healthcare infrastructure. The United States leads regional market growth with substantial investment in veterinary regenerative medicine research and clinical applications. High awareness of advanced treatment options among pet owners and veterinarians drives adoption. Presence of regenerative medicine product manufacturers and research institutions supports innovation. Established veterinary referral networks and specialty practices provide service accessibility. With high pet spending and advanced veterinary infrastructure, North America maintains its dominant market position.

Region with highest CAGR:

Over the forecast period, the Asia-Pacific region is anticipated to exhibit the highest CAGR, driven by rising pet ownership, increasing disposable incomes, growing awareness of advanced veterinary treatments, and expanding veterinary infrastructure across countries including China, Japan, Australia, and Southeast Asia. The region's rapidly growing pet population and expanding middle class create substantial demand for advanced therapeutic options. Growing investment in veterinary education and specialty training is expanding regenerative medicine capabilities. Increasing pet insurance coverage supports affordability. As veterinary healthcare develops and awareness of regenerative options grows, Asia Pacific delivers the fastest veterinary regenerative medicine market growth globally.

Key players in the market

Some of the key players in Veterinary Regenerative Medicine Market include VetStem Biopharma, Inc., Zoetis Inc., Boehringer Ingelheim International GmbH, Dechra Pharmaceuticals Limited, Ardent Animal Health, Medrego Ltd., Vetbiologics, Vetherapy, Celavet, Integra LifeSciences Holdings Corporation, Gallant Therapeutics, Enso Discoveries, Animal Cell Therapies, VetCell Therapeutics, Magellan BioMedical, KeraVet Bio, VetStem Europe, and EquiCell.

Key Developments:

In April 2026, Gallant Therapeutics announced an exclusive commercial distribution partnership with MWI Animal Health to market and supply its pipeline of ready-to-use, off-the-shelf allogeneic stem cell therapies across US veterinary networks.

In September 2025, Zoetis expanded clinical education programs around autologous blood-derived biologics, highlighting long-term synovial joint recovery data for equine athletes treated with regenerative systems.

In April 2025, Vetirus Pharmaceuticals completed the acquisition of Enso Discoveries, integrating its patented, device-agnostic Rebound PRP(TM) and Rebound PRF(R) platelet therapy platforms into a global veterinary biologics pipeline.

In March 2025, Medrego expanded clinical distribution of allogeneic and autologous mesenchymal stem cell preparations (CaniCell and EquiCell) across European veterinary specialty practices for treating severe osteoarthritis and ligament tears.

Product Types Covered:

  • Stem Cell Therapy
  • Platelet-Rich Plasma (PRP)
  • Bone Marrow Aspirate Concentrate (BMAC)
  • Growth Factor Therapies
  • Tissue Engineering Products and Biomaterials
  • Extracellular Vesicles and Exosome-Based Therapies
  • Other Regenerative Medicine Products

Animal Types Covered:

  • Companion Animals
  • Equine
  • Livestock Animals
  • Other Animals

Applications Covered:

  • Orthopedics and Musculoskeletal Disorders
  • Trauma and Wound Care
  • Dermatology and Skin Regeneration
  • Neurology and Nerve Regeneration
  • Cardiology and Cardiovascular Repair
  • Ophthalmology and Ocular Regeneration
  • Dentistry and Oral Tissue Regeneration
  • Internal Organ Repair
  • Other Applications

End Users Covered:

  • Veterinary Hospitals and Specialty Centers
  • Independent Veterinary Clinics
  • Veterinary Research and Academic Institutes
  • Veterinary Rehabilitation Centers
  • Biotechnology and Pharmaceutical Companies
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Veterinary Regenerative Medicine Market, By Product Type

  • 5.1 Stem Cell Therapy
    • 5.1.1 Mesenchymal Stem Cells (MSCs)
    • 5.1.2 Adipose-Derived Stem Cells
    • 5.1.3 Bone Marrow-Derived Stem Cells
    • 5.1.4 Umbilical Cord-Derived Stem Cells
    • 5.1.5 Other Stem Cell Types
  • 5.2 Platelet-Rich Plasma (PRP)
  • 5.3 Bone Marrow Aspirate Concentrate (BMAC)
  • 5.4 Growth Factor Therapies
  • 5.5 Tissue Engineering Products and Biomaterials
    • 5.5.1 Scaffolds
    • 5.5.2 Biological Matrices
  • 5.6 Extracellular Vesicles and Exosome-Based Therapies
  • 5.7 Other Regenerative Medicine Products

6 Global Veterinary Regenerative Medicine Market, By Animal Type

  • 6.1 Companion Animals
    • 6.1.1 Dogs
    • 6.1.2 Cats
  • 6.2 Equine
    • 6.2.1 Race Horses
    • 6.2.2 Performance and Sport Horses
    • 6.2.3 Recreational Horses
  • 6.3 Livestock Animals
    • 6.3.1 Cattle
    • 6.3.2 Swine
    • 6.3.3 Poultry
  • 6.4 Other Animals

7 Global Veterinary Regenerative Medicine Market, By Application

  • 7.1 Orthopedics and Musculoskeletal Disorders
    • 7.1.1 Osteoarthritis and Joint Disorders
    • 7.1.2 Tendon and Ligament Injuries
    • 7.1.3 Fracture and Bone Repair
    • 7.1.4 Cartilage Repair
  • 7.2 Trauma and Wound Care
    • 7.2.1 Acute Wounds
    • 7.2.2 Chronic Wounds
    • 7.2.3 Surgical Wound Healing
  • 7.3 Dermatology and Skin Regeneration
  • 7.4 Neurology and Nerve Regeneration
  • 7.5 Cardiology and Cardiovascular Repair
  • 7.6 Ophthalmology and Ocular Regeneration
  • 7.7 Dentistry and Oral Tissue Regeneration
  • 7.8 Internal Organ Repair
  • 7.9 Other Applications

8 Global Veterinary Regenerative Medicine Market, By End User

  • 8.1 Veterinary Hospitals and Specialty Centers
  • 8.2 Independent Veterinary Clinics
  • 8.3 Veterinary Research and Academic Institutes
  • 8.4 Veterinary Rehabilitation Centers
  • 8.5 Biotechnology and Pharmaceutical Companies
  • 8.6 Other End Users

9 Global Veterinary Regenerative Medicine Market, By Geography

  • 9.1 North America
    • 9.1.1 United States
    • 9.1.2 Canada
    • 9.1.3 Mexico
  • 9.2 Europe
    • 9.2.1 United Kingdom
    • 9.2.2 Germany
    • 9.2.3 France
    • 9.2.4 Italy
    • 9.2.5 Spain
    • 9.2.6 Netherlands
    • 9.2.7 Belgium
    • 9.2.8 Sweden
    • 9.2.9 Switzerland
    • 9.2.10 Poland
    • 9.2.11 Rest of Europe
  • 9.3 Asia Pacific
    • 9.3.1 China
    • 9.3.2 Japan
    • 9.3.3 India
    • 9.3.4 South Korea
    • 9.3.5 Australia
    • 9.3.6 Indonesia
    • 9.3.7 Thailand
    • 9.3.8 Malaysia
    • 9.3.9 Singapore
    • 9.3.10 Vietnam
    • 9.3.11 Rest of Asia Pacific
  • 9.4 South America
    • 9.4.1 Brazil
    • 9.4.2 Argentina
    • 9.4.3 Colombia
    • 9.4.4 Chile
    • 9.4.5 Peru
    • 9.4.6 Rest of South America
  • 9.5 Rest of the World (RoW)
    • 9.5.1 Middle East
      • 9.5.1.1 Saudi Arabia
      • 9.5.1.2 United Arab Emirates
      • 9.5.1.3 Qatar
      • 9.5.1.4 Israel
      • 9.5.1.5 Rest of Middle East
    • 9.5.2 Africa
      • 9.5.2.1 South Africa
      • 9.5.2.2 Egypt
      • 9.5.2.3 Morocco
      • 9.5.2.4 Rest of Africa

10 Strategic Market Intelligence

  • 10.1 Industry Value Network and Supply Chain Assessment
  • 10.2 White-Space and Opportunity Mapping
  • 10.3 Product Evolution and Market Life Cycle Analysis
  • 10.4 Channel, Distributor, and Go-to-Market Assessment

11 Industry Developments and Strategic Initiatives

  • 11.1 Mergers and Acquisitions
  • 11.2 Partnerships, Alliances, and Joint Ventures
  • 11.3 New Product Launches and Certifications
  • 11.4 Capacity Expansion and Investments
  • 11.5 Other Strategic Initiatives

12 Company Profiles

  • 12.1 VetStem Biopharma, Inc.
  • 12.2 Zoetis Inc.
  • 12.3 Boehringer Ingelheim International GmbH
  • 12.4 Dechra Pharmaceuticals Limited
  • 12.5 Ardent Animal Health
  • 12.6 Medrego Ltd.
  • 12.7 Vetbiologics
  • 12.8 Vetherapy
  • 12.9 Celavet
  • 12.10 Integra LifeSciences Holdings Corporation
  • 12.11 Gallant Therapeutics
  • 12.12 Enso Discoveries
  • 12.13 Animal Cell Therapies
  • 12.14 VetCell Therapeutics
  • 12.15 Magellan BioMedical
  • 12.16 KeraVet Bio
  • 12.17 VetStem Europe
  • 12.18 EquiCell

List of Tables

  • Table 1 Global Veterinary Regenerative Medicine Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Veterinary Regenerative Medicine Market Outlook, By Product Type (2023-2034) ($MN)
  • Table 3 Global Veterinary Regenerative Medicine Market Outlook, By Stem Cell Therapy (2023-2034) ($MN)
  • Table 4 Global Veterinary Regenerative Medicine Market Outlook, By Mesenchymal Stem Cells (MSCs) (2023-2034) ($MN)
  • Table 5 Global Veterinary Regenerative Medicine Market Outlook, By Adipose-Derived Stem Cells (2023-2034) ($MN)
  • Table 6 Global Veterinary Regenerative Medicine Market Outlook, By Bone Marrow-Derived Stem Cells (2023-2034) ($MN)
  • Table 7 Global Veterinary Regenerative Medicine Market Outlook, By Umbilical Cord-Derived Stem Cells (2023-2034) ($MN)
  • Table 8 Global Veterinary Regenerative Medicine Market Outlook, By Other Stem Cell Types (2023-2034) ($MN)
  • Table 9 Global Veterinary Regenerative Medicine Market Outlook, By Platelet-Rich Plasma (PRP) (2023-2034) ($MN)
  • Table 10 Global Veterinary Regenerative Medicine Market Outlook, By Bone Marrow Aspirate Concentrate (BMAC) (2023-2034) ($MN)
  • Table 11 Global Veterinary Regenerative Medicine Market Outlook, By Growth Factor Therapies (2023-2034) ($MN)
  • Table 12 Global Veterinary Regenerative Medicine Market Outlook, By Tissue Engineering Products and Biomaterials (2023-2034) ($MN)
  • Table 13 Global Veterinary Regenerative Medicine Market Outlook, By Scaffolds (2023-2034) ($MN)
  • Table 14 Global Veterinary Regenerative Medicine Market Outlook, By Biological Matrices (2023-2034) ($MN)
  • Table 15 Global Veterinary Regenerative Medicine Market Outlook, By Extracellular Vesicles and Exosome-Based Therapies (2023-2034) ($MN)
  • Table 16 Global Veterinary Regenerative Medicine Market Outlook, By Other Regenerative Medicine Products (2023-2034) ($MN)
  • Table 17 Global Veterinary Regenerative Medicine Market Outlook, By Animal Type (2023-2034) ($MN)
  • Table 18 Global Veterinary Regenerative Medicine Market Outlook, By Companion Animals (2023-2034) ($MN)
  • Table 19 Global Veterinary Regenerative Medicine Market Outlook, By Dogs (2023-2034) ($MN)
  • Table 20 Global Veterinary Regenerative Medicine Market Outlook, By Cats (2023-2034) ($MN)
  • Table 21 Global Veterinary Regenerative Medicine Market Outlook, By Equine (2023-2034) ($MN)
  • Table 22 Global Veterinary Regenerative Medicine Market Outlook, By Race Horses (2023-2034) ($MN)
  • Table 23 Global Veterinary Regenerative Medicine Market Outlook, By Performance and Sport Horses (2023-2034) ($MN)
  • Table 24 Global Veterinary Regenerative Medicine Market Outlook, By Recreational Horses (2023-2034) ($MN)
  • Table 25 Global Veterinary Regenerative Medicine Market Outlook, By Livestock Animals (2023-2034) ($MN)
  • Table 26 Global Veterinary Regenerative Medicine Market Outlook, By Cattle (2023-2034) ($MN)
  • Table 27 Global Veterinary Regenerative Medicine Market Outlook, By Swine (2023-2034) ($MN)
  • Table 28 Global Veterinary Regenerative Medicine Market Outlook, By Poultry (2023-2034) ($MN)
  • Table 29 Global Veterinary Regenerative Medicine Market Outlook, By Other Animals (2023-2034) ($MN)
  • Table 30 Global Veterinary Regenerative Medicine Market Outlook, By Application (2023-2034) ($MN)
  • Table 31 Global Veterinary Regenerative Medicine Market Outlook, By Orthopedics and Musculoskeletal Disorders (2023-2034) ($MN)
  • Table 32 Global Veterinary Regenerative Medicine Market Outlook, By Osteoarthritis and Joint Disorders (2023-2034) ($MN)
  • Table 33 Global Veterinary Regenerative Medicine Market Outlook, By Tendon and Ligament Injuries (2023-2034) ($MN)
  • Table 34 Global Veterinary Regenerative Medicine Market Outlook, By Fracture and Bone Repair (2023-2034) ($MN)
  • Table 35 Global Veterinary Regenerative Medicine Market Outlook, By Cartilage Repair (2023-2034) ($MN)
  • Table 36 Global Veterinary Regenerative Medicine Market Outlook, By Trauma and Wound Care (2023-2034) ($MN)
  • Table 37 Global Veterinary Regenerative Medicine Market Outlook, By Acute Wounds (2023-2034) ($MN)
  • Table 38 Global Veterinary Regenerative Medicine Market Outlook, By Chronic Wounds (2023-2034) ($MN)
  • Table 39 Global Veterinary Regenerative Medicine Market Outlook, By Surgical Wound Healing (2023-2034) ($MN)
  • Table 40 Global Veterinary Regenerative Medicine Market Outlook, By Dermatology and Skin Regeneration (2023-2034) ($MN)
  • Table 41 Global Veterinary Regenerative Medicine Market Outlook, By Neurology and Nerve Regeneration (2023-2034) ($MN)
  • Table 42 Global Veterinary Regenerative Medicine Market Outlook, By Cardiology and Cardiovascular Repair (2023-2034) ($MN)
  • Table 43 Global Veterinary Regenerative Medicine Market Outlook, By Ophthalmology and Ocular Regeneration (2023-2034) ($MN)
  • Table 44 Global Veterinary Regenerative Medicine Market Outlook, By Dentistry and Oral Tissue Regeneration (2023-2034) ($MN)
  • Table 45 Global Veterinary Regenerative Medicine Market Outlook, By Internal Organ Repair (2023-2034) ($MN)
  • Table 46 Global Veterinary Regenerative Medicine Market Outlook, By Other Applications (2023-2034) ($MN)
  • Table 47 Global Veterinary Regenerative Medicine Market Outlook, By End User (2023-2034) ($MN)
  • Table 48 Global Veterinary Regenerative Medicine Market Outlook, By Veterinary Hospitals and Specialty Centers (2023-2034) ($MN)
  • Table 49 Global Veterinary Regenerative Medicine Market Outlook, By Independent Veterinary Clinics (2023-2034) ($MN)
  • Table 50 Global Veterinary Regenerative Medicine Market Outlook, By Veterinary Research and Academic Institutes (2023-2034) ($MN)
  • Table 51 Global Veterinary Regenerative Medicine Market Outlook, By Veterinary Rehabilitation Centers (2023-2034) ($MN)
  • Table 52 Global Veterinary Regenerative Medicine Market Outlook, By Biotechnology and Pharmaceutical Companies (2023-2034) ($MN)
  • Table 53 Global Veterinary Regenerative Medicine Market Outlook, By Other End Users (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.